Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:45 - Any
Updated:3/27/2019
Start Date:August 2016
End Date:March 2021
Contact:Gretchen Peichel, RN
Email:gpeichel@umn.edu
Phone:(612) 626 6237

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a
predictor of cancer treatment-related cardiotoxicity.


Inclusion Criteria:

- Stage I-III breast cancer or lymphoma with a >2 year life expectancy

- A treatment plan that includes anthracyclines and/or trastuzumab

- Age >45 years

- Able to hold breath for 10 seconds

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

- Refusal or inability to provide informed consent

- Known heart failure or LVEF <50%

- Heart rate over 100 bpm

- Renal dysfunction with GFR <30 mL/min/1.73m2

- Participants with pacemakers, defibrillators, functioning neurostimulator devices or
other implanted electronic devices

- Symptomatic claustrophobia

- Plans to move within 24 months of enrollment
We found this trial at
1
site
Univ of Minnesota
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Chetan Shenoy, MBBS
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials